Intravesical chemotherapy (i.e., placement of the drug directly in the bladder) with mitomycin C is beneficial for patients with superficial bladder cancer who are at high risk of recurrence, but standard therapy is empirically based and patient response rates have been variable, in part because of inadequate drug delivery. We carried out a prospective, two-arm, randomized, multi-institutional phase III trial to test whether enhancing the drug's concentration in urine would improve its efficacy. 
Intravesical chemotherapy, as adjuvant to surgical removal of superficial bladder cancer, has been shown to be beneficial in patients at high risk for recurrence (1) . However, the selection of the drug and the administration regimen have largely been empiric. We completed a series of studies (2) (3) (4) (5) (6) (7) (8) to determine the basis of the incomplete and variable response of patients to intravesical mitomycin C and doxorubicin, evaluating drug sensitivity of bladder tumors in patients, plasma and urine pharmacokinetics in animals and patients, and spatial drug distribution in bladder tissues in animals and patients. On the basis of these studies, we concluded that the variable and incomplete response is partly due to the insensitivity of highly malignant tumors to the drug and partly due to inadequate drug delivery to tumor cells. The inadequate drug delivery, in turn, is a result of dilution, in part, of the drug solution by residual urine in the bladder, dilution by continuous urine production during the 2-hour treatment, and the inability of the drug to penetrate the deep-muscle layers in the bladder. In the case of mitomycin C, instability of the drug in acidic urine is an additional problem.
These findings suggested several approaches to enhance the mitomycin C concentration in urine and thereby to enhance the drug concentration in tumor cells: 1) increasing the dose from the conventional 20 mg to 40 mg, 2) reducing the dosing volume from the conventional 40 mL to 20 mL, 3) minimizing the volume of residual urine at the time of treatment, 4) reducing urine production before and during treatment by voluntary dehydration, and 5) alkalinizing the urine by use of oral sodium bicarbonate. We used computer simulation to show the pharmacokinetics and pharmacodynamics of such modified intravesical mitomycin C therapy (9) . On the basis of the simulation results, we hypothesized that enhancing drug delivery to tumor cells would enhance the recurrence-free fraction from 20% to 40% (9) .
This study tested this hypothesis in an international, multicenter, prospective phase III trial in patients with superficial bladder cancer who are at high risk for recurrence. The primary objective of the trial was to compare the efficacy of an optimized regimen designed to enhance drug delivery with that of a standard regimen commonly used in the community. The secondary objective was to determine the toxicity of the optimized regimen and to establish factors that may be used to predict response to intravesical mitomycin C therapy.
SUBJECTS AND METHODS

Selection of Patients
The study population consisted of patients with histologically proven transitional cell carcinoma of the bladder who were considered at high risk for tumor recurrence because of the presence of at least one of the following: 1) two or more episodes of histologically proven Ta, Tis, or T1 transitional cell carcinoma (10); 2) multifocal bladder tumors (defined as three or more papillary tumors present simultaneously or Tis involving at least 25% of the bladder surface area and/or in two or more biopsy sites); and 3) primary or solitary tumors that were more than 5 cm in size, were grade III (11), or exhibited DNA aneuploidy. All patients were registered for randomization within 34 days (mean and median values of 20 days) of transurethral bladder tumor resection, had adequate bone marrow reserve (white blood cell count >4000/mm 3 and platelet count >100 000/ mm 3 ), had adequate renal function (serum creatinine level ഛ2.0 mg/dL or 177 M), and had a Karnofsky performance score of 50-100. Exclusion criteria included prior treatment with mitomycin C within 56 weeks of registration, prior muscle-invasive (T2-T4) transitional cell carcinoma of the bladder, concurrent malignancy within 5 years of registration (except for basal cell carcinoma), and pregnancy.
Study Protocol
Fourteen academic and research centers participated in the trial. The study protocol was approved by the institutional review board of the individual study sites. Written informed consent, which detailed the treatments of the two arms, was obtained from all patients. Because this trial was sponsored by the National Cancer Institute (Bethesda, MD), we also obtained the mandated approval from the Office of Protection Against Research Risk of the National Institutes of Health (Bethesda, MD). Appropriate clearance from the State Department (Washington, DC) was also obtained for the non-U.S. sites.
Patient randomization and data collection were performed in a central office located at The Ohio State University Comprehensive Cancer Center (Columbus). Patients were randomly allocated to one of the two treatment arms by use of stratified blocked randomization across 16 (2 × 2 × 2 × 2) strata resulting from four prognostic criteria: 1) presence versus absence of Tis tumor, 2) grade III versus grades I and II tumors, 3) multifocal versus unifocal tumors, and 4) recurrent versus primary tumors. Information on tumor pathology provided by the treatment site was used for stratification. Within a given stratum, treatment allocation was balanced in 10 patient blocks. Stratification based on prognostic factors was performed to ensure treatment group equability and to obviate the need for post hoc covariate adjustment.
The starting date of patient accrual at the 14 study sites ranged from October 1992 to March 1998. The accrual ended on March 23, 1999 . A total of 230 patients were enrolled and randomly assigned to either the standard-treatment arm (111 patients) or the optimized-treatment arm (119 patients). Eight of the enrolled patients (three from the standard arm and five from the optimized arm) were found subsequently not to meet the eligibility criteria. Of the remaining 222 patients (108 in the standard arm and 114 in the optimized arm), two (one in each arm) had protocol violations; 12 did not complete six treatments because of refusal (one in the standard arm and two in the optimized arm), because of toxicity (two in each arm), or because of other reasons (two in the standard arm and three in the optimized arm); two (one in each arm) refused follow-up; and five (two in the standard arm and three in the optimized arm) had incomplete data. The remaining 201 patients (99 in the standard arm and 102 in the optimized arm) were evaluable (Fig. 1) . The median follow-up time was 11.7 months as of March 31, 2000. Patients in both arms received six weekly treatments with intravesical mitomycin C dissolved in 20 mL of sterile water. Among the 217 patients who received intravesical chemotherapy, 214 received mitomycin C from BristolMyers Squibb (Princeton, NJ) and three received mitomycin C from Kyowa Hakko Kogyo Co. (Tokyo, Japan). The major differences between the two arms were the higher dose and the manipulations used to maintain a high drug concentration in the urine in the optimized arm. Patients allocated to the optimized arm were instructed to refrain from drinking fluids for 8 hours before and during intravesical mitomycin C treatment. They were also given oral doses of 1.3 g of sodium bicarbonate the night before, the morning of, and 30 minutes before drug treatment. Just before treatment, a Foley catheter was inserted to empty the bladder. The postvoid residual urine volume was measured by use of a bladder ultrasound instrument (Diagnostic Ultrasound, Redmond, WA) and was reduced, if necessary, by repositioning the catheter and/or by changing the position of the patient. This procedure was repeated until the residual urine volume was less than 10 mL. Mitomycin C (40 mg in 20 mL of sterile water) was then instilled intravesically through the Foley catheter by gravity. Drug solution was retained in the bladder for 2 hours.
Patients allocated to the standard arm were not instructed to refrain from drinking fluids and did not receive oral sodium bicarbonate. In these patients, bladders were emptied via the Foley catheter, but no additional measures were undertaken to minimize the residual urine volume. These patients received a lower dose of mitomycin C (20 mg in 20 mL of sterile water) that was retained in the bladder for the same 2-hour duration. Our previous pharmacokinetic study (5) of the mitomycin treatment used in the standard arm has shown that there is minimal systemic absorption of the drug, with plasma concentrations well below the threshold concentration associated with hematologic toxicity. Hence, complete blood cell counts were not mandatory in the standard-treatment arm and were done at the discretion of the treating physician. Because the systemic pharmacokinetics of mitomycin C administered by the optimized-treatment regimen had not been studied previously, the protocol called for mandatory complete blood cell counts in the first 20 patients in the optimized arm 1 week after the first dose was administered (i.e., before administration of the second dose) and, in the absence of toxicity in these 20 patients, termination of this mandate in subsequent patients. As shown in the "Results" section, hematologic toxicity was indeed absent. Hence, mandatory blood cell counts were discontinued, and monitoring of hematologic toxicity in subsequent patients was done at the discretion of the treating physician. Samples of urine, serum, and tumors were obtained for companion pharmacologic studies, whose results will be reported elsewhere.
Patient Follow-up
Patients were followed with cystoscopic and cytologic examination quarterly for the first 2 years, biannually for years 3-5 at the discretion of the treating physician, and annually thereafter. Investigators were encouraged to perform a biopsy on suspicious areas for tumor recurrence. Tumors were determined to have recurred when the patient had a positive post-treatment biopsy or a positive cytology. The time to recurrence was defined as the length of time from randomization to the first pathologic or cytologic evidence of tumor recurrence.
Patient Evaluability
Patients were considered to be evaluable when they completed the six weekly treatments, provided complete treatment and follow-up data, and had no protocol violations.
Statistical Analysis
As stated above, our computer simulation results (9) predicted that the changes adopted in the optimized-treatment arm, compared with the standardtreatment arm, will enhance the recurrence-free fraction from 20% to 40%. By using these predicted values and by assuming exponential failure-time distribution, a median time to recurrence of 13 months in the standard regimen, and a 20% nonevaluable rate, we calculated that a sample size of 290 patients, or 116 recurrences, would be required for a two-sided ␣ of 0.05 and a power of 0.80. The sample size of 290 was calculated on the basis of a 2-year accrual period with final analysis in year 3, and the recurrence number of 116 was calculated on the basis of a ratio of 1.7 for the median time to recurrence in the optimized arm to that in the standard arm. Because of a slower-than-expected accrual rate and the resulting longer-than-anticipated follow-up period, the 116 recurrences were attained with a reduced sample size of 230 patients.
Two interim analyses with O'Brien and Fleming (12)-adjusted levels of statistical significance were conducted after accrual of 100 and 200 patients. Neither interim analysis reached the necessary level of statistical significance for early termination. Hence, patient accrual continued until 116 recurrences were observed.
Analysis of the primary endpoint of the time to recurrence was performed by use of Kaplan-Meier survival analysis with log-rank tests. Overall and stratified log-rank tests were used. The proportion of patients free of recurrence at 5 years was also analyzed. Analyses were performed both on an intent-to-treat basis and on the evaluable group. Comparisons of continuous data were performed by Student's t test, and discrete data were analyzed by use of Fisher's exact tests or chi-square tests. All tests used a two-sided .05 level of significance.
RESULTS
Patient Characteristics
The patient populations in the two treatment arms were comparable with respect to demographics (Table 1) , disease characteristics used for randomization stratification (Table 2) , and history of intravesical therapy (Tables 1 and 3 ). The only demographic variable that approached statistical significance was age (P ‫ס‬ .07); the average age of the patients in the optimized *No statistically significant differences were observed. The numbers of patients with recurrent disease were 77 in the standard-treatment arm and 83 in the optimized-treatment arm. BCG ‫ס‬ bacille Calmette-Guérin.
†Other drugs include Regressin, Intron A, bropiramine, and unknown. arm was approximately 3 years older than that of the patients in the standard arm.
Toxicity
For patients in the standard arm, the protocol did not call for mandatory monitoring of hematologic toxicity. However, at their physicians' discretion, 19 patients in the standard arm were evaluated for hematologic toxicity. Only one patient, who had a history of demyelinating radiculopathy and was receiving weekly immunoglobulin treatments, showed an alteration of white blood cell count (a transient reduction from a pretreatment level of 8100/mm 3 to a level of 3700/mm 3 5 days after the first treatment, followed by a return to 4500, 4100, and 4900/mm 3 during the subsequent three treatments). No hematologic toxicity was observed for the remaining patients.
For patients in the optimized arm, the protocol called for the monitoring of hematologic toxicity 1 week after the first dose of mitomycin C in the first 20 patients to determine whether this previously untested regimen would be associated with unexpected toxicity. We chose this time point because we had found previously that systemic drug absorption is maximal after the first dose, with nearly undetectable absorption after the subsequent doses and hematologic toxicity takes several days to become apparent (5) . No hematologic toxicity was observed in the first 20 patients treated in the optimized arm. Hence, a mandatory complete blood cell count was discontinued. In the additional 31 patients who were monitored at the discretion of the treating physicians, no hematologic toxicity was observed.
There were minimal differences in nonhematologic toxicity in the two treatment arms (Table 4) . Dysuria was the only toxic effect that was statistically significantly higher in the optimized arm than in the standard arm, but it did not result in a higher frequency of treatment termination in the optimized arm. (Treatment was terminated in one patient each in both arms because of
pyridium) occurred in four patients in the optimized arm but in no patients in the standard arm. Twelve patients who complained of dysuria or cystitis (two in the standard arm and 10 in the optimized arm) were treated prophylactically with antibiotics for possible urinary-tract infection. The two pa- *A total of 107 patients in the standard-treatment arm and 111 in the optimized-treatment arm received at least one dose of mitomycin C. No toxicity data were reported for one standard-treatment arm patient.
†P ‫ס‬ .01. None of the other toxic effects achieved statistical significance. ‡Urinary-tract infection refers to patients with a positive urine culture.
Fig. 2. Treatment outcome in intent-to-treat (left) and evaluable (right) groups.
Results of the Kaplan-Meier analysis are shown. Symbols indicate censored patients, and error bars show 95% confidence intervals (CIs). 1) In the intentto-treat group of patients (n ‫ס‬ 230), the median time to recurrence was 11.8 months in the standard-treatment arm (n ‫ס‬ 111) and 29.1 in the optimizedtreatment arm (n ‫ס‬ 119). At 3 years after treatment, 28.4% (95% CI ‫ס‬ 18.8% to 38%) of the patients in the standard-treatment arm and 44.5% (95% CI ‫ס‬ 34.7% to 54.3%) of the patients in the optimized-treatment arm were recurrence free. At 5 years after treatment, the recurrence-free percentages were 24.6% (95% CI ‫ס‬ 14.9% to 34.3%) and 41% (95% CI ‫ס‬ 30.9% to 51.1%), respectively. 2) In the evaluable patients (n ‫ס‬ 201), the median time to recurrence was 11.3 months in the standard-treatment arm (n ‫ס‬ 99) and 29.1 in the optimizedtreatment arm (n ‫ס‬ 102). At 3 years after treatment, 27.1% (95% CI ‫ס‬ 17.5% to 36.7%) of the patients in the standard-treatment arm and 44.4% (95% CI ‫ס‬ 34.1% to 54.7%) of the patients in the optimized-treatment arm were recurrence free. At 5 years after treatment, the recurrence-free percentages were 23.5% (95% CI ‫ס‬ 14% to 33%) and 42.6% (95% CI ‫ס‬ 32.3% to 52.9%), respectively. tients in the standard arm turned out to have negative urine cultures. Of the 10 patients in the optimized arm, one had a positive urine culture, two had a positive urinalysis by urinalysis strip that was not verified by urine cultures, five had negative cultures, and two were not tested. Among the two arms, the optimized arm showed a trend of a higher incidence of cystitis and a lower incidence of urinary frequency, although the differences did not reach statistical significance. Patients in both arms showed a similar ability to tolerate the treatment regimen.
Tumor Recurrence
Kaplan-Meier analyses of recurrence in both the intent-totreat group and the evaluable group indicated that, in both groups, patients in the optimized arm had a statistically significantly longer time to recurrence and a higher recurrence-free fraction at all time points than patients in the standard arm (Fig. 2 ). Improvements were found across all stratification risk groups (tumor stage, grade, focality, and recurrence by stratified *The analyses of treatment effect in the subgroups are post hoc analyses for which the study was not specifically designed. These are presented to indicate that a trend of improved therapy was observed for all risk groups. Statistical significance was not reached in several subgroups because of the low numbers of patients in several subgroups. †Estimated probability of remaining free of recurrence at 5 years. ‡Analysis of differences in time to recurrence by log-rank test. §The difference in time to recurrence for all patients was also evaluated by the stratified log-rank test, with stratification for the randomization criteria. The overall stratified log-rank statistic was associated with a P<.001, with P values for the individual strata of .004 for stage, .005 for grade, .002 for focality, and .005 for recurrence.
(10). ¶NR ‫ס‬ no patients have reached the end of the 5-year follow-up period. ն(11).
log-rank test), and improvements or trends toward improvement were found in all tested subgroups (Tables 5 and 6 ). There was no sex-related difference in treatment outcome, as determined by Kaplan-Meier analysis with log-rank test.
An unexpected finding of this study was an association between race and treatment outcome. In an attempt to enhance the accrual of minorities, we included several major metropolitan areas in our study sites. Nevertheless, African-Americans accounted for only 3% of the patients accrued to the study. The risk factors for the six African-American patients (three in each treatment arm) were similar to those for all patients (grade:
, in all of the African-American patients, the disease recurred in less than 1 year. The difference in the recurrence data between the African-American and Caucasian patients was highly statistically significant (Fig. 3) , although the very small number of African-American patients in this unplanned analysis makes a conclusion tentative. In the protocol design, race had not been included as a stratification factor because there were no data to suggest differential responses to mitomycin C by different ethnic groups. However, the even distribution of the African- *The analyses of treatment effect in the subgroups are post hoc analyses for which the study was not specifically designed. These are presented to indicate that a trend of improved therapy was observed for all risk groups. Statistical significance was not reached in several subgroups because of the low numbers of patients in several subgroups. †Estimated probability of remaining free of recurrence at 5 years. ‡Analysis of differences in time to recurrence by log-rank test. §NR ‫ס‬ no patients have reached the end of the 5-year follow-up period. (10).
¶(11).
American patients in the two treatment arms indicates that the low response rate in these patients was not due to the difference in the treatment received.
DISCUSSION
Intravesical mitomycin C therapy has been used for more than two decades as adjuvant treatment of superficial bladder cancer. The doses and treatment conditions have been based empirically. Multiple studies [e.g., (13, 14) ] evaluated different doses (range, 20-60 mg) and different instillation durations (range, 0.5-2 hours). Some of the studies indicate a higher response rate for treatments by use of a higher dose and/or a longer instillation, whereas other studies do not support this conclusion. The inconsistent results are partly due to the highly variable and incomplete patient response rate and partly due to the relatively small patient sample size of some of the studies, which precludes meaningful statistical evaluation. We have shown (2) (3) (4) (5) (6) (7) (8) that the variable patient response rate may be due to several physiologic variables (i.e., residual urine volume at the time of treatment, urine production rate, and urine pH), which reduce the drug concentration in urine and thereby lower drug delivery to tumor cells. This study was designed to test the hypothesis that drug delivery to tumor cells could be enhanced and the response rate could be improved by controlling the physiologic variables and by increasing the dose. Our results demonstrate that these changes reduced the recurrence rate and lengthened the median time to recurrence. These improvements in therapeutic efficacy were found for all stratification groups, and they were achieved without clinically significant enhancement in toxicity. On the basis of these results, we recommend that intravesical mitomycin C therapy be given under the conditions described for the optimized arm, i.e., a dose of 40 mg at a concentration of 2 mg/mL in water, complete bladder emptying just before dose administration, fluid restriction, and oral bicarbonate to alkalinize the urine.
The standard arm in the present investigation used an induction intravesical mitomycin C therapy that is nearly identical to the induction therapy used in the Southwest Oncology Group (SWOG) protocol 8795. The SWOG study was a randomized prospective comparison with bacille Calmette-Guérin (BCG) (15) . Both protocols used 20 mg of mitomycin C at a concentration of 1 mg/mL of water, and neither controlled residual urine volume, urine production rate, or urine pH. A minor difference was that the maximal time to treatment after transurethral bladder tumor resection was 14 days in the SWOG protocol but 28 days in this study. The extension was for logistical reasons, including waiting for laboratory results, obtaining consent from patients, and waiting for the availability of appointments. The SWOG protocol also used a monthly maintenance therapy with mitomycin C. This study did not include a maintenance therapy because the benefit of maintenance therapy has not been established. The median time to recurrence was 22 months in the SWOG study and 12 months in the standard arm of this study. This difference may be due to the different patient populations in the two studies. This study included patients who had had prior mitomycin C and BCG therapy, whereas the SWOG trial excluded these patients. We speculate that this difference resulted in a worse prognosis for the patients in our study.
An unexpected finding in this study was the ineffectiveness of intravesical mitomycin C therapy in African-American patients. The small number of African-American patients and the unplanned nature of the analysis limit the confidence that can be placed in this finding. Nevertheless, we speculate that a genetic basis for the differential response may exist. Mitomycin C undergoes metabolic activation by quinone reductases. The two major reductive enzymes are DT-diaphorase and cytochrome p450 reductase, and laboratory studies (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) have indicated a correlation between the antitumor activity of mitomycin C and the activity of these enzymes. Whether there is genetic variation in enzyme activity or a relationship between enzyme activity and treatment outcome is not known and requires further investigation.
Intravesical BCG is often used as the first-line therapy for superficial bladder cancer, in part because of its relatively low cost. Seven randomized prospective clinical trials have compared the recurrence rates of bladder cancer after treatment with intravesical mitomycin C with those after treatment with intravesical BCG. Three studies (15, 26, 27) showed intravesical BCG to be superior, whereas four studies (28) (29) (30) (31) showed no difference. However, the mitomycin C regimens in these earlier trials were not designed to optimize the drug delivery to tumors. For example, in the SWOG protocol 8795, the mitomycin C regimen was similar to the less effective standard arm used in our study. Our results raise the possibility that mitomycin C, when used as described in the more effective optimized regimen, represents a viable alternative to BCG in the treatment of superficial bladder cancer. In addition, the relatively low toxicity of mitomycin C, as compared with BCG, represents an important advantage. Hence, a randomized prospective trial comparing the optimized mitomycin C regimen with BCG is warranted. 3 . Kaplan-Meier curves of the risk of recurrence among evaluable AfricanAmerican and Caucasian patients. The median time to recurrence was 5.2 months in the African-American patients (n ‫ס‬ 6) and 16 months in the Caucasian patients (n ‫ס‬ 188). The remaining seven evaluable patients were of other ethnic groups and were not included in the analysis. The percentage of patients who were recurrence free at 5 years was 0% in the African-American patients and 34% in the Caucasian patients (P<.001, log-rank test for time to recurrence). Symbols indicate censored patients, and error bars show 95% confidence intervals.
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